Early detection of prostate cancer. Part I: Prior probability and effectiveness of tests

Annals of Internal Medicine

Volumn 126, Issue 5, 1997, Pages 394-406

  Coley, Christopher M ^b   Barry, Michael J ^a   Fleming, Craig ^c   Mulley, Albert G ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD UNIVERSITY   (United States)

^c Health Outcomes Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; FINGER; HUMAN; MALE; MAXIMUM LIKELIHOOD METHOD; MEDICAL INFORMATION; NEEDLE BIOPSY; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; PROBABILITY; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; RECEIVER OPERATING CHARACTERISTIC; RECTUM; RISK FACTOR; STATISTICAL ANALYSIS; TRANSRECTAL ULTRASONOGRAPHY;

EID: 0031041477     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-126-5-199703010-00010     Document Type: Article

References (181)

1. Parker SU Tong T, Bolden S, Wingo PA. Cancer statistics, 1996 CA Cancer J Clin. 1996;46:5-27
2. Stamey TA, Freiha FS, McNeal JE, Redwine EA, Whittemore AS, Schmid HP. Localized prostate cancer. Relationship of tumor volume to clinical signficance for treatment of prostate cancer. Cancer. 1993;71(3 Suppl):933-8.
3. Ries LA, Hankey BF, Miller BA, Hartman AM, Edwards BK, eds. Cancer statistics review 1973-88. Bethesda, MD: National Cancer Institute; 1991. NIH Pub No. 91-2789.
4. Schmidt JD, Mettlin CJ, Natarajan N, Peace BB, Beart RW Jr, Winchester DP, et al. Trends in patterns of care for prostatic cancer, 1974-1983: results of surveys by the American College of Surgeons. J Urol. 1986;136:416-21.
5. Garnick MB. Prostate cancer: screening, diagnosis, and management. Ann Intern Med. 1993;118:804-18.
6. Mettlin C, Jones GW, Murphy GP. Trends in prostate cancer care in the United States, 1974-1990: observations from the patient care evaluation studies of the American College of Surgeons Commission on Cancer. CA Cancer J Clin. 1993;43:83-91.
7. Gann PH. Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA. 1995;273:289-94.
8. Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organconfined prostate cancer is increased through prostate-specific antigen-based screening. JAMA. 1993;270:948-54.
9. Richie JP, Catalona WJ, Ahmann FR, Hudson MA, Scardino PT, Flangan RC, et al. Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal examination. Urology. 1993;42:365-74.
10. Sackett DL, Haynes RB, Tugwell P. Clinical Epidemiology: A Basic Science for Clinical Medicine. Boston: Little, Brown; 1985.
11. Black WC, Welch HG. Advances in diagnostic imaging and overestimations of disease prevalence and the benefits of therapy. N Engl J Med. 1993;328:1237-43.
12. Morrison AS. Intermediate determinants of mortality in the evaluation of screening. Int J Epidemiol. 1991;20:642-50.
13. Gerber GS, Thompson IM, Thisted R, Chodak GW. Disease-specific survival following routine prostate cancer screening by digital rectal examination. JAMA. 1993;269:61-4.
14. Ohori M, Wheeler TM, Dunn JK, Stamey TA, Scardino PT. The pathological features and prognosis of prostate cancer detectable with current diagnostic tests. J Urol. 1994;152(5 Pt 2):1714-20.
15. Epstein Jl, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA. 1994;271:368-74.
16. Lu-Yao GL, Greenberg ER. Changes in prostate cancer incidence and treatment in USA. Lancet. 1994;343:251-4.
17. Fowler FJ Jr, Barry MJ, Lu-Yao G, Roman A, Wasson J, Wennberg JE, et al. Patient-reported complications and follow-up treatment after radical prostatectomy: the National Medicare Experience: 1988-1990 (updated June 1993). Urology. 1993;42:622-9.
18. Jonler M, Messing EM, Rhodes PR, Bruskewitz RC. Sequelae of radical prostatectomy. Br J Urol. 1994;74:352-8.
19. Chodak GW, Thisted RA, Gerber GS, Johansson JE, Adolfsson J, Jones GW, et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med. 1994;330:242-8.
20. Fleming C, Wasson JH, Albertsen PC, Barry MJ, Wennberg JE. A decision analysis of alternative treatment strategies for clinically localized prostate cancer. Prostate Patient Outcomes Research Team. JAMA. 1993;269:2650-8.
21. Krahn MD, Mahoney JE, Eckman MH, Trachtenberg J, Pauker SG, Detsky AS. Screening for prostate cancer. A decision analytic view. JAMA. 1994;272:773-80.
22. Terris MK, Haney DJ, Johnstone IM, McNeal JE, Stamey TA. Prediction of prostate cancer volume using prostate-specific antigen levels, transrectal ultrasound, and systematic sextant biopsies. Urology. 1995;45:75-80.
23. Stamey TA. Making the most out of six systematic sextant biopsies. Urology. 1995;45:2-12.
24. Wolf JS Jr, Shinohara K, Carroll PR, Narayan P. Combined role of transrectal ultrasonography, Gleason score, and prostate-specific antigen in predicting organ-confined prostate cancer. Urology. 1993;42:131-7.
25. Gohagan JK, Prorok PC, Kramer BS, Cornett JE. Prostate cancer screening in the prostate, lung, colurectal and ovarian cancer screening trial of the National Cancer Institute. J Urol. 1994;152(5 Pt 2):1905-9.
26. Wilt TJ, Brawer MK. The Prostate Cancer Intervention Versus Observational Trial: a randomized trial comparing radical prostatectomy versus expectant management for the treatment of clinically localized prostate cancer. J Urol. 1994;152(5 Pt 2): 1910-4.
27. Prorok P. The National Cancer Institute Multi-Screening Trial. Can J Oncol. 1994;4(Suppl 1):98-9.
28. Schroder FH. The European Screening Study for Prostate Cancer. Can J Oncol. 1994;4(Suppl 1):102-5.
29. Thompson IM, Zeidman EJ. Current uroiogical practice: routine urological examination and early detection of carcinoma of the prostate. J Urol. 1992;148(2 Pt 1):326-30.
30. Voss JD. Prostate cancer, screening, and prostate-specific antigen: promise or peril? J Gen Intern Med. 1994;9:468-74.
31. Demers RY, Swanson GM, Weiss LK, Kau TV. Increasing incidence of cancer of the prostate. The experience of black and white men in the Detroit metropolitan area. Arch Intern Med 1994;154:1211-6.
32. Potosky AL, Miller BA, Albertsen PC, Kramer BS. The role of increasing detection tn the rising incidence of prostate cancer. JAMA. 1995;273:548-52.
33. Mettlin C, Jones G, Averetle H, Gusberg SB, Murphy GP. Defining and updating the American Cancer Society guidelines for the cancer-related checkup: prostate and endometrial cancers. CA Cancer J Clin. 1993;43:42-6.
34. Screening for prostate cancer: commentary on the recommendations of the Canadian Task Force on the Periodic Health Examination. The U.S. Preventive Services Task Force, Am J Prev Med. 1994;10:187-93.
35. Periodic health examination, 1991 update: 3. Secondary prevention of prostate cancer. Canadian Task Force on the Periodic Health Examination. Can Med Assoc J. 1991;145:413-28.
36. Adami HO, Baron JA, Rothman KJ. Ethics of a prostate cancer screening trial. Lancet. 1994;343:958-60.
37. Sox HC Jr. Preventive health services tn adults. N Engl J Med. 1994;330:1589-95.
38. Lee JM. Screening and informed consent. N Engl J Med. 1993;328:438-40.
39. Aronowitz R. To screen or not to screen. What is the question? [Editorial] J Gen Intern Med. 1995;10:295-7.
40. Brett AS. The mammography and prostate-specific antigen controversies: implications for patient-physician encounters and public policy. J Gen Intern Med. 1995;10:266-70.
41. Coley CM, Barry MJ, Fleming C, Wasson JH, Fahs MC, Oesterling JE. Should Medfcare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part II: Early detection strategies. Urology. 1995;46:T25-41.
42. Scott R Jr. Mutchnik DL, Laskowski TZ, Schmalhorst WR. Carcinoma of the prostate in elderly men: incidence, growth characteristics and clinical significance. J Urol. 1969;101:602-7.
43. Franks LM. Latent carcinoma of the prostate. Journal of Pathology and Bacteriology. 1954;68:603-16.
44. Gaynor EP. Zur frage des prostatakrebes. Virchows Arch Pathol Anat Physiol Klin Med. 1938;301:602-52.
45. Baron E, Angrist A. Incidence of occult adenocarcinoma of the prostate after 50 years of age. Archives of Pathology. 1941;32:787-93.
46. Edwards C, Steinthorsson N, Nicholson D. An autopsy study of latent prostatic cancer. Cancer. 1953;6:531-54.
47. Lundberg S, Berge T. Prostatic carcinoma. An autopsy study. Scand J Urol Nephrol. 1970;4:93-7.
48. Halpert B, Schmalhorst WR. Carcinoma of the prostate in patients 70 to 79 years old. Cancer. 1966;19:695-8.
49. Sakr WA, Haas GP, Cassin BF, Pontes JE, Crissman JD. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients, J Urol. 1993;150(2 Pt 1):379-85.
50. McNeal JE, Bostwick DG, Kindrachuk RA, Redwine EA, Freiha FS, Stamey TA. Patterns of progression in prostate cancer. Lancet. 1986;1:60-3.
51. Ransohoff DF, Feinstein AR. Problems of spectrum and bias in evaluating the efficacy of diagnostic tests. N Engl J Med. 1978;299:926-30.
52. Friedman GD, Hiatt RA, Quesenberry CP Jr, Selby JV, Case-control study of screening for prostatic cancer by digital rectal examinations. Lancet. 1991;337:1526-9.
53. Helzlsoucr KJ, Newby J, Comstock GW. Prostate-specific antigen levels and subsequent prostate cancer: potential for screening. Cancer Epidemiol Biomarkers Prev. 1992;1:537-40.
54. Vallancien G, Prapotnich D, Sibert L, Lugagne PM, Veillon B, Brisset JM, et al. Comparison of the efficacy of digital rectal examination and transrectal ultrasonography in the diagnosis of prostatic cancer. Eur Urol. 1989;16:321-4.
55. Vallancien G, Prapotnich D, Veillon B, Brisset JM, Andre-Bougaran J. Systematic prostatic biopsies in 100 men with no suspicion of cancer on digital rectal examination. J Urol. 1991;146:1308-12.
56. Guinan P, Bush I, Ray V, Vieth R, Rao R, Bhatti R. The accuracy of the rectal examination in the diagnosis of prostate carcinoma. N Engl J Med. 1980;303:499-503.
57. Guinan P, Ray P, Bhatti R, Rubenstein M. An evaluation of five tests to diagnose prostate cancer. Prog Clin Biot Res. 1987;243A:551-8.
58. Naito S, Kimiya K, Hasegawa Y, Kumazawa J. Digital examination and transrectal ultrasonography in the diagnosis of prostatic cancer. Eur Urol. 1988;14:356-9.
59. Hammerer P, Huland H. Systematic sextant biopsies in 651 patients referred for prostate evaluation. J Urol. 1994;151:99-102.
60. Guthman DA, Wilson TM, Blute ML, Bergstralh EJ, Zincke H, Oesterling JE. Biopsy-proved prostate cancer in 100 consecutive men with benign digital rectal examination and elevated serum prostate-specific antigen level. Prevalence and pathologic characteristics. Urology. 1993;42:150-4.
61. Partin AW, Carter HB, Chan DW, Epstein JI, Oesterling JE, Rock RC, et al. Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol. 1990;143:747-52.
62. Partin AW, Yoo J, Carter HB, Pearson JD, Chan DW, Epstein Jl, et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol. 1993;150:110-4.
63. Oesterling JE, Chan DW, Epstein JI, Kimball AW Jr, Bruzek DJ, Rock RC, et al. Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J Urol. 1988;139:766-72.
64. Winter HI, Bretton PR, Herr HW. Preoperative prostate-specific antigen in predicting pathologic stage and grade after radical prostatectonny. Urology. 1991;38:202-5.
65. Lange PH, Ercole CJ, Lightner DJ, Fraley EE, Vessella R. The value of serum prostate specific antigen determinations before and after radical prostatectomy. J Urol. 1989;141:873-9.
66. Hudson MA, Bahnson RR, Catalona WJ. Clinical use of prostate specific antigen in patients with prostate cancer. J Urol. 1989;142:1011-7.
67. Kleer E, Urson-Keller JJ, Zincke H, Oesterling JE. Ability of preoperative serum prostate-specific antigen value to predict pathologic stage and DNA ploidy. influence of clinical stage and tumor grade. Urology. 1993;41:207-16.
68. Rainwater LM, Morgan WR, Klee GG, Zincke H, Prostate-specific antigen testing in untreated and treated prostatic adenocarcinoma. Mayo Clin Proc. 1990;65:1118-26.
69. Ercole CJ, Lange PH, Mathisen M, Chiou RK, Reddy PK, Vessella RU et al. Prostate specific antigen and prostatic aod phosphatase in the monitoring and staging of patients with prostatic cancer. J Urol. 1987;138:1181-4.
70. Catalona WJ, Smith OS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991;324:1156-61
71. Brawer MK, Chetner MP, Beatie J, Buchner DM, Vessella RL, Lange PH. Screening for prostatic carcinoma with prostate specific antigen. J Urol. 1992;147(3 Pt 2):841-5.
72. Chodak GW, Keller P, Schoenberg HW. Assessment of screening for prostate cancer using the digital rectal examination. J Urol. 1989;141:1136-8.
73. Boring CC, Squires TS, Tong T, Montgomery S. Cancer statistics, 1994. CA Cancer J Clin. 1994;44:7-26.
74. Steele GD Jr, Winchester DP, Menck HR, Murphy GP. Clinical highlights from the National Cancer Data Base: 1993. CA Cancer J Clin. 1993;43:71-82.
75. Ries LA, Miller BA, Hankey BF, Kosary CL, Narras A, Edwards BK, eds. SEER Cancer Statistics Review, 1973-1991: Tables and Graphs. Bethesda, MD: National Cancer Institute; 1994. NIH publication no. 94-2789.
76. Pienta KJ, Esper PS. Risk factors for prostate cancer, Ann Intern Med. 1993;118:793-803.
77. Nomura AM, Kolonel LN. Prostate cancer: a current perspective. Epidemiol Rev. 1991;13:200-27.
78. Steinberg GD, Carter BS, Beaty TH, Childs B, Walsh PC. Family history and the risk of prostate cancer. Prostate. 1990;17:337-47.
79. Spitz MR. Currier RD, Fueger JJ, Babian RJ, Newell GR. Familial patterns of prostate cancer: a case-control analysis. J Urol. 1991;146:1305-7.
80. Baquet CR, Horm JW, Gibbs T, Greenwald P. Socioeconomic factors and cancer incidence among blacks and whites. J Natl Cancer Inst. 1991;83:551-7.
81. Giovannucci E, Ascherio A, Rimm EB, Colditz GA, Stampfer MJ, Willett WC. A prospective cohort study of vasectomy and prostate cancer in US men. JAMA, 1993:269:873-7.
82. Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Stolley PD, Shapiro S. Vasectomy and the risk of prostate cancer. Am J Epidemiol. 1990;132:1051-5.
83. Howards SS, Peterson HB. Vasectomy and prostate cancer. Chance, bias, or a causal relationship? [Editorial] JAMA. 1993;269:913-4.
84. Guess HA. Is vasectomy a risk factor for prostate cancer? Eur J Cancer. 1993;29A:1055-60.
85. Giovannucci E, Rimm EB, Colditz GA, Stampfer MJ, Ascherio A, Chute CC, et al. A prospective study of dietary fat and risk of prostate cancer. J Natl Cancer Inst. 1993;85:1571-9.
86. Montie JE, Wood DP Jr, Pontes JE, Boyett JM, Levin HS. Adenocarcinoma of the prostate in cystoprostatectomy specimens removed for bladder cancer. Cancer. 1989;63:381-5.
87. Zincke H. Re: Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of followup [Letter]. J Urol. 1994;151:435.
88. Gleason OF. Histologie grading and clinical staging of prostatic carcinoma. In: Tannenbaum M, ed. Urologic Pathology: The Prostate. Philadelphia: Lea & Febiger; 1977:171-97.
89. Montie JE. 1992 staging system for prostate cancer. Semin Urol. 1993;11:10-3.
90. Stamey TA, Freiha FS, McNeal JE, Redwine EA, Whittemore AS, Schmid HP. Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer. 1993;71(3Suppl):933-8.
91. Mills SE, Fowler JE Jr. Gleason histologie grading of prostatic carcinoma. Correlations between biopsy and prostatectomy specimens. Cancer. 1986;57:346-9.
92. Garnett JE, Oyasu R, Grayhack JT. The accuracy of diagnostic biopsy specimens in predicting tumor grades by Gleason's classification in radical prostatectomy specimens. J Urol. 1984;131:690-3.
93. Aihara M, Wheeler TM, Ohori M, Scardino PT. Heterogeneity of prostate cancer in radical prostatectomy specimens. Urology. 1994;43:60-7.
94. Epstein Jl, Carmichael MJ, Pizov G, Walsh PC, Influence of capsular penetration on progression following radical prostatectomy: a study of 196 cases with long-term followup. J Urol. 1993;150:135-41.
95. Kabalin JN, McNeal JE, Price HM, Freiha FS, Stamey TA. Unsuspected adenocarcinoma of the prostate in patients undergoing cystoprostatectomy for other causes: incidence, histology and morphometric observations. J Urol. 1989;141:1091-4.
96. Johansson JE, Adame HO, Andersson SO, Bergstrom R, Holmberg L, Krusemo UB. High 10-year survival rate in patients with early, untreated prostatic cancer. JAMA. 1992;267:2191-6.
97. Alexander RB, Maguire MG, Epstein JI, Walsh PC. Pathological stage is higher in older men with clinical stage 81 adenocarcinoma of the prostate. J Urol. 1989;141:880-2.
98. Dhom G. Epidemiologic aspects of latent and clinically manifest carcinoma of the prostate. J Cancer Res Clin Oncol. 1983;106:210-8.
99. Greene DR, Rogers E, Wessels EC, Wheeler TM, Taylor SR, Santucci RA, et al. Some small prostate cancers are nondipioid by nuclear image analysis: correlation of deoxyribonudeic acid ploidy status and pathological features. J Urol. 1994;151:1301-7.
100. Myers RP, Larson-Keller JJ, Bergstralh EJ, Zincke H, Oesterling JE, Lieber MM. Hormonal treatment at time of radical retropubic prostatectomy for stage D1 prostate cancer: results of long-term followup. J Urol. 1992;147(3 Pt 2):910-5.
101. Van den Ouden D, Tribukait B, Blom JH, Fossa SD, Kurth KH, ten Kate FJ, et al. Deoxyribonudeic acid ploidy of core biopsies and metastatic lymph nodes of prostate cancer patients: impact on time to progression. The European Organization for Research and Treatment of Cancer Genitourinary Group. J Urol. 1993;150(2 Pt 1):400-6.
102. Smith DS, Catalona WJ. Interexaminer variability of digital rectal examination in detecting prostate cancer. Urology. 1995;45:70-4.
103. Varenhorst E, Berglund K, Lofman O, Pedersen K. Inter-observe variation in assessment of the prostate by digital rectal examination. Br J Urol. 1993;72:173-6.
104. Flanigan RC, Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, et al. Accuracy of digital rectal examination and transrectal ultrasonography in localizing prostate cancer. J Urol. 1994;152(5 Pt 1):1506-9.
105. Thompson IM, Ernst JJ, Gangai MP, Spence DR. Adenocarcinoma of the prostate: results of routine urological screening. J Urol. 1984;132:690-2.
106. Pedersen KV, Carlsson P, Varenhorst E, Lofman O, Berglund K. Screening for carcinoma of the prostate by digital rectal examination in a randomly selected population. BMJ. 1990;300:1041-4.
107. Gustafsson O, Norming U, Almgard LE, Frederiksson A, Gustavsson G, Harvig B, et al. Diagnostic methods in the detection of prostate cancer: a study of randomly selected population of 2,400 men. J Urol. 1992;148:1827-31.
108. Varenhorst E, Carlsson P, Capik E, Lofman O, Pederson KV. Repeated screening for carcinoma of the prostate by digital rectal examination in a randomly selected population. Acta Oncol. 1992;31:815-21.
109. Oesterling JE, Suman VJ, Zincke H, Bostwick DG. PSA-detected (clinical stage T1c or BO) prostate cancer. Pathologically significant tumors. Urol Clin North Am. 1993;20:687-93.
110. Mold JW, Holtgrave DR, Bisonni RS, Marley DS, Wright RA, Spann SJ. The evaluation and treatment of men with asymptomatic prostate nodules in primary care: a decision analysts. J Fam Pract. 1992;34:561-8.
111. Love RR, Fryback DG, Kimbrough SR. A cost-effectiveness analysis of screening for carcinoma of the prostate by digital examination. Med Decis Making. 1985;5:263-78.
112. Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol. 1991;145:907-23.
113. Cupp MR, Oesterling JE. Prostate-specific antigen, digital rectal examination, and transrectal ultrasonography: their roles in diagnosing early prostate cancer. Mayo Clin Proc. 1993;68:297-306.
114. Ruckle HC, Klee GG, Oesterling JE. Prostate-specific antigen: concepts for staging prostate cancer and monitoring response to therapy. Mayo Clin Proc. 1994;69:69-79.
115. Brawn PN, Speights VO, Kuhl D, Riggs M, Spiekerman AM, McCord RG, et al. Prostate-specific antigen levels from completely sectioned, clinically benign, whole prostates. Cancer. 1991;68:1592-9.
116. Oesterling JE, Rice DC, Glenski WJ, Bergstralh EJ. Effect of cystoscopy, prostate biopsy, and transurethral resection of prostate on serum prostate-specific antigen concentration. Urology. 1993;42:276-82.
117. Klomp ML, Hendrikx AJ, Keyzer JJ. The effect of transrectal ultrasonography (TRUS) including digital rectal examination (ORE) of the prostate on the level of prostate specific antigen (PSA). Br J Urol. 1994;73:71-4.
118. Yuan JJ, Coplen DE, Petros JA, Figenshau RS, Ratliff TU Smith DS, et al. Effects of rectal examination, prostatic massage, ultrasonography and needle biopsy on serum prostate specific antigen levels. J Urol. 1992;147(3 Pt 2):810-4.
119. Crawford ED, Schutz MJ, Clejan S, Drago J, Resnick Ml, Chodak GW, et al. The effect of digital rectal examination on prostate-specific antigen levels. JAMA, 1992;267:2227-8.
120. Hudson MA. Prostate-specific antigen and the clinician. Advances in Urology. 1993;6:157-86.
121. Vessella RL, Lange PH. Issues in the assessment of PSA immunoassays. Urol Clin North Am. 1993;20:607-19.
122. Vessella RL, Noteboom J, Lange PH. Evaluation of the Abbott IMx automated immunoassay of prostate-specific antigen. Clin Chem. 1992;38:2044-54.
123. Graves HC, Wehner N, Stamey TA. Comparison of a polyclonal and monoclonal immunoassay for PSA: need for an international antigen standard. J Urol. 1990;144:1516-22.
124. Terris MK, Stamey TA. Utilization of polycional serum prostate specific antigen levels in screening for prostate cancer: a comparison with corresponding monoclonal values, Br J Urol. 1994;73:61-4.
125. Marcus MA, Moore JJ. Comparison of three immunoassays for the quantification of prostate specific antigen in human serum. Clin Chem. 1993;39:1193.
126. Stamey TA, Chen Z, Prestigiacomo A. Serum prostate specific antigen binding alpha 1-antichymotrypsin: influence of cancer volume, location and therapeutic selection of resistant clones. J Urol. 1994;152(5 Pt 1): 1510-4.
127. Graves HC Standardization of immunoassays for prostate-specific antigen. A problem of prostate-specific antigen complexation or a problem of assay design? Cancer. 1993;72:3141-4.
128. Jacobsen SJ, Lilja H, Klee GG, Wright GL Jr, Pettersson K, Oesterling JE. Comparability of the Tandem-R and IMx assays for the measurement of serum prostate-specific antigen. Urology. 1994;44:512-8.
129. Oesterling JE, Cooner WH, Jacobsen SJ, Guess HA, Lieber MM. Influence of patient age on the serum PSA concentration. An important clinical observation. Urol Clin North Am. 1993;20:671-80.
130. Collins GN, Lee RJ, McKelvie GB, Rogers AC, Hehir M. Relationship between prostate specific antigen, prostate volume, and age in the benign prostate. Br J Urol. 1993;71:445-50.
131. Oesterting JE, Jacobsen SJ, Cooner WH. The use of age-specific reference ranges for serum prostate specific antigen in men 60 years old or older. J Urol. 1995;153:1160-3.
132. Dalkin BL, Ahmann FR, Kopp JB. Prostate specific antigen levels in men older than 50 years without clinical evidence of prostatic carcinoma. J Urol. 1993;150:1837-9.
133. Mettlin C, Murphy GP, Lee F, Littrup PJ, Chesley A, Babian R, et al. Characteristics of prostate cancer detected in the American Cancer Society-National Prostate Cancer Detection Project. J Urol. 1994;152(5 Pt 2):1737-40.
134. Catalona WJ, Hudson MA, Scardino PT, Richie JP, Ahmann FR, Flanigan RC, et al. Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves. J Urol. 1994;152(6 Pt 1):2037-42.
135. Brawer MK, Beatie J, Wener MH, Vessella RL, Preston SD, Lange PH. Screening for prostatic carcinoma with prostate specific antigen: results of the second year. J Urol. 1993;150:106-9.
136. Mettlin C, Murphy GP, Ray P, Shanberg A, Toi A, Chesley A, et al. American Cancer Society-National Prostate Cancer Detection Project. Results from multiple examinations using transrectal ultrasound, digital rectal examination, and prostate specific antigen. Cancer. 1993;71(3 Suppl):891-8.
137. Smith DS, Catalona WJ. The nature of prostate cancer detected through prostate specific antigen based screening. J Urol. 1994;152(5 Pt 2):1732-6.
138. Bretton PR. Prostate-specific antigen and digital rectal examination in screening for prostate cancer: a community-based study: a community-based study. South Med J. 1994;87:720-3.
139. Muschenheim F, Omarbasha B, Kardjian PM, Mondou EN. Screening for carcinoma of the prostate with prostate specific antigen. Ann Clin Lab Sci. 1991;21:371-80.
140. Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter cfrnical trial of 6,630 men. J Urol. 1994;151:1283-90.
141. Labrie F, Dupont A, Suburu R, Cusan L, Tremblay M, Gomez JL, et al. Serum prostate specific antigen as pre-screening test for prostate cancer. J Urol. 1992;147(3 Pt 2):846-52.
142. Mettlin C, Lee F, Drago J, Murphy GP. The American Cancer Society National Prostate Cancer Detection Project. Findings on the detection of early prostate cancer in 2425 men. Cancer. 1991;67:2949-58.
143. Babaian RJ, Mettlin C, Kane R, Murphy GP, Lee F, Drago JR, et al. The relationship of prostate-specific antigen to digital rectal examination and transrectal ultrasonography. Findings of the American Cancer Society National Prostate Cancer Detection Project. Cancer. 1992;69:1195-200.
144. Sershon PD, Barry MJ, Oesterling JE. Serum prostate-specific antigen discriminates weakly between men with benign prostatic hyperplasia and patients with organ-confined prostate cancer. Eur Urol. 1994;25:281-7.
145. Benson MC, Whang IS, Pantuck A, Ring K, Kaplan SA, Olsson CA, et al. Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol. 1992;147(3 Pt 2):815-6.
146. Benson MC, Whang IS, Olsson CA, McMahon DJ, Cooner WH. The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol. 1992;147:817-21.
147. Bazinet M, Meshref AW, Trudel C, Aronson S, Peloquin F, Nachabe M, et al. Prospective evaluation of prostate-specific antigen density and systematic biopsies for early detection of prostatic carcinoma. Urology. 1994;43:44-52.
148. Semjonow A, Hamm M, Rathert P, Hertle L. Prostate-specific antigen corrected for prostate volume improves differentiation of benign prostatic hyperplasia and organ-confined prostatic cancer. Br J Urol. 1994;73:538-43.
149. Rommel FM, Agusta VE, Breslin JA, Huffnagle HW, Pohl CE, Sieber PR, et al. The use of prostate specific antigen and prostate specific antigen density in the diagnosis of prostate cancer in a community based urology practice. J Urol. 1994;151:88-93.
150. Shinohara K, Wolf JS Jr, Narayan P, Carroll PR. Comparison of prostate specific antigen with prostate specific antigen density for 3 clinical applications. J Urol. 1994;152:120-3.
151. Catalona WJ, Richie JP, deKernion JB, Ahmann FR, Ratliff TL, Dalkin BL, et al. Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves. J Urol. 1994;152(6 Pt 1):2031-6.
152. Brawer MK, Aramburu EA, Chen GL, Preston SD, Ellis WJ. The inability of prostate specific antigen index to enhance the predictive value of prostate speafic antigen in the diagnosis of prostatic carcinoma. J Urol. 1993;150(2 Pt 1):369-73.
153. Lookner OH, Crawford ED, Donohue RE, et al. Prostate specific antigen and prostate speofic antigen density in cases of pathologically proven prostate cancer [Abstract]. J Urol. 1993;149:414A.
154. Bare R, Hart L, McCullough DL Correlation of prostate-specific antigen and prostate-specific antigen density with outcome of prostate biopsy. Urology. 1994;43:191-6.
155. Carter HB, Pearson JD, Metter EJ, Brant U, Chan DW, Andres R, et al. Longitudinal evaluation of prostate-spectfic antigen levels in men with and without prostate disease. JAMA. 1992;267:2215-20.
156. Carter HB, Pearson JD. PSA velocity for the diagnosis of early prostate cancer. A new concept. Urol Clin North Am. 1993;20:665-70.
157. Riehmann M, Rhodes PR, Cook TD, Grose GS, Bruskewitz RC. Analysis of variation in prostate-specific antigen values. Urology. 1993;42:390-7.
158. Barry MJ, Girman CJ, O'Leary MP, Walker-Corkery ES, Binkowitz BS, Cockett AT, et al. Using repeated measures of symptom score, uroflowmetry and prostate specific antigen in the clinical management of prostate disease. Benign Prostatic Hyperplasia Treatment Outcomes Study Group. J Urol. 1995;153:99-103.
159. Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliff TL, et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA. 1995;274:1214-20.
160. Stenman UH, Hakama M, Knekt P, Aromaa A, Teppo U Leinonen J. Serum concentrations of prostate specific antigen and its complex with alpha 1-antichymotrypsin before diagnosis of prostate cancer. Lancet. 1994;344:1594-8.
161. Carter HB, Hamper UM, Sheth S, Sanders RC, Epstein Jl, Walsh PC. Evaluation of transrectal ultrasound in the early detection of prostate cancer. J Urol. 1989;142:1008-10.
162. Shinohara K, Wheeler TM, Scardino PT, The appearance of prostate cancer on transrectal ultrasonography: correlations of imaging and pathological examinations. J Urol. 1989;142:76-82.
163. Terris MK, Freiha FS, McNeal JE, Stamey TA. Efficacy of transrectal ultrasound for identification of clinically undetected prostate cancer. J Urol. 1991;146:78-84.
164. Stilmant MM, Kuligowska E. Transrectal ultrasound screening for prostatic adenocarcinoma with histopathological correlation. Factors affecting specificity. Cancer. 1993;71:2041-7.
165. Chancellor MB, VanAppledorn CA. Value of transrectal prostate ultrasonography pre-transurethral prostatectorny in screening for occult prostate carcinoma. Urology. 1993;41:590-3.
166. Hammerer P, Loy V, Dieringer J, Huland H. Prostate cancer in nonurological patients with normal prostates on digital rectal examination. J Urol. 1992;147(3 Pt 2):833-6.
167. Cooner WH, Mosley BR, Rutherford CL Jr, Beard JH, Pond HS, Terry WJ, et al. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J Urol. 1990;143:1146-54.
168. Keetch DW, Catalona WJ, Smith DS. Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. J Urol. 1994;151:1571-4.
169. Terris MK, McNeal JE, Stamey TA. Detection of clinically significant prostate cancer by transrectal ultrasound-guided systematic biopsies. J Urol. 1992;148:829-32
170. Webb JA, Shanmuganathan K, McLean A. Complications of ultrasound-guided transperineal prostate biopsy. A prospective study. Br J Urol. 1993;72:775-7.
171. Collins GN, Uoyd SN, Hehir M, McKelvie GB. Multiple transrectal ultrasound-guided prostatic biopsies-true morbidity and patient acceptance. Br J Urol. 1993;71:460-3.
172. Aus G, Hermansson CG, Hugosson J, Pedersen KV. Transrectal ultrasound examination of the prostate: complications and acceptance by patients. Br J Urol. 1993;71:457-9.
173. Desmond PM, Clark J, Thompson IM, Zeidman EJ, Mueller EJ. Morbidity with contemporary prostate biopsy. J Urol. 1993;150(5 Pt 1):1425-6.
174. Schmidt JD, Mettlin Cl, Natarajan N, Peace BB, Bean RW Jr, Winchester DP, et al. Trends in patterns of care for prostatic cancer, 1974-1983: results of surveys by the American College of Surgeons. J Urol. 1986;136:416-21.
175. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA, et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA. 1993;270:860-4.
176. Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hypertrophy in the community. Lancet. 1991;338:469-71.
177. Chute CG, Panser LA, Girman Cl, Oesterling JE, Guess HA, Jacobsen SJ, et al. The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol. 1993;150:85-9.
178. Coffield KS, Speights VO, Brawn PN, Riggs MW. Ultrasound detection of prostate cancer in postmortem specimens with histological correlation. J Urol. 1992;147(3 Pt 2):822-6.
179. Walsh PC. Using prostate-specific antigen to diagnose prostate cancer: sailing in uncharted waters [Editorial]. Ann Intern Med. 1993;119:948-9.
180. Kramer BS, Brown ML, Prorok PC, Potosky AL, Gohagan JK. Prostate cancer screening: what we know and what we need to know. Ann Intern Med. 1993;119:914-23.
181. Lang CA, Ransohoff DF. Fecal occult blood screening for colorectal cancer. is mortality reduced by chance selection for screening colonoscopy? JAMA. 1994;271:1011-3.